Bacitracin Powder, derived from Bacillus licheniformis, acts as a potent antibiotic, targeting bacterial peptidoglycan to inhibit cell wall synthesis. This makes it effective against a wide range of Gram-positive bacteria in medical and research settings.
In clinical applications, Bacitracin Powder is used to treat infections caused by Staphylococcus and Streptococcus species. Its mechanism disrupts cell wall synthesis, effectively treating skin and soft tissue infections.
In laboratories, Bacitracin Powder is crucial in microbial culture media, acting as a selective agent. It inhibits Gram-positive bacteria growth while allowing Gram-negative bacteria to thrive, aiding in the isolation and identification of specific strains.
Additionally, Bacitracin Powder is essential for studying bacterial resistance mechanisms, helping researchers understand how bacteria develop resistance to antibiotics. This insight is vital for developing strategies to combat antibiotic resistance.
In summary, Bacitracin Powder’s potent antibacterial properties, role in clinical treatment and microbial culture, and contribution to resistance studies highlight its importance in medical research and treatment.
| Cat. Number | AS-2033 |
| CAS Number | 1405-87-4 |
| MDL Number | MFCD00062640 |
| Pubchem | 310267241 |
| Molecular Weight | 1422.70 g/mol |
| Molecular Formula | C66H103N17O16S |
| Storage Temperature | +4 °C |
| Form and Color | Powder / White to light beige or light yellow |
| pH (10 kU/ml) | 5.5 – 7.5 |
| Loss on Drying | ≤ 5% |
| Identification (IR) | To conform the standard |
| Heavy Metals | ≤ 30 ppm |
| Bacitracin A | ≥ 40% |
| Bacitracin A+B1+B2+B3 | ≥ 70% |
| Potency (Dried basis) | ≥ 65 IU/mg |
